Table 3.

Stratification analysis for the associations of TRMT6 gene polymorphisms with neuroblastoma risk in children from Jiangsu Province

Variables	rs451571 (cases/controls)		AOR (95% CI) ^a	P ^a	rs236110 (cases/controls)		AOR (95% CI) ^a	P ^a	Protective genotypes (cases/controls)		AOR (95% CI) ^a	P ^a
Variables	TT	TC/CC	AOR (95% CI) ^a	P ^a	CC	CA/AA	AOR (95% CI) ^a	P ^a	0–2	3–5	AOR (95% CI) ^a	P ^a
Age, month
≤ 18	82/82	57/57	1.00 (0.62–1.61)	0.997	87/88	52/51	1.03 (0.63–1.68)	0.902	84/83	55/56	0.97 (0.60–1.57)	0.900
> 18	170/191	93/143	0.73 (0.52–1.02)	0.065	179/205	84/129	0.75 (0.53–1.05)	0.091	188/191	75/143	0.53 (0.38–0.75)	0.0003
Gender
Females	121/130	70/95	0.79 (0.53–1.18)	0.246	128/138	63/87	0.78 (0.52–1.17)	0.229	124/131	67/94	0.75 (0.51–1.12)	0.162
Males	131/143	80/105	0.83 (0.57–1.21)	0.336	138/155	73/93	0.88 (0.60–1.29)	0.515	148/143	63/105	0.58 (0.39–0.86)	0.006
Sites of origin
Adrenal gland	56/273	37/200	0.90 (0.57–1.42)	0.664	52/293	41/180	1.28 (0.82–2.01)	0.277	65/274	28/199	0.60 (0.37–0.96)	0.034
Retroperitoneal	103/273	64/200	0.85 (0.59–1.22)	0.372	120/293	47/180	0.64 (0.43–0.94)	0.022	113/274	54/199	0.66 (0.45–0.96)	0.028
Mediastinum	82/273	38/200	0.63 (0.41–0.97)	0.035	82/293	38/180	0.75 (0.49–1.16)	0.196	81/274	39/199	0.66 (0.43–1.01)	0.057
Others	10/273	8/200	1.09 (0.42–2.81)	0.862	10/293	8/180	1.30 (0.50–3.35)	0.589	11/274	7/199	0.88 (0.33–2.30)	0.789
Clinical stages
I + II + 4s	113/273	60/200	0.73 (0.51–1.05)	0.094	113/293	60/180	0.87 (0.60–1.25)	0.447	118/274	55/199	0.64 (0.45–0.93)	0.019
III + IV	95/273	68/200	0.98 (0.68–1.40)	0.907	106/293	57/180	0.88 (0.60–1.27)	0.487	110/274	53/199	0.66 (0.46–0.97)	0.032

AOR, adjusted odds ratio; CI, confidence interval

^a Adjusted for age and gender, omitting the correspondence factor

^b Protective genotypes were carriers with rs236170 AG/GG, rs451571 TC/CC, rs6139878 AA, rs236188 GA/AA, and rs236110 CC/CA genotypes